おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Genticel
company
About
Gentiel develops therapeutic vaccines for the prevention of cervical cancer in HPV infected women.
- 11 - 50
Details
- Last Funding Type
- Series D
- Last Funding Money Raised
- €18.20M
- Industries
- Biotechnology,Medical Device,Therapeutics
- Founded date
- Jan 1, 2001
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Genticel is a French clinical stage biotechnology company founded by Benedikt Timmerman in 2001 and focused on the development of innovative immunotherapies designed to treat virus infections and virus-induced diseases. Genticel aims to become a leader in immunotherapy in multiple indications, starting with HPV and HPV induced diseases such as cervical cancer.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
€18.20M $17.70M
Genticel has raised a total of
€18.20M $17.70M
in funding over 2 rounds. Their latest funding was raised on
Apr 24, 2013 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 24, 2013 | Series D | €18.20M | 1 | — | — | Detail |
| Apr 5, 2010 | Series C | $17.70M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Genticel is funded by 1 investors.
InnoBio Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
InnoBio Fund
|
— | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
